Clinical Decision-Making for Drug-Resistant Tuberculosis
Medical graduates working in the field of drug resistant tuberculosis (DR TB) are invited to join this 11-week blended learning course on the clinical aspects and decision making of DR TB diagnosis and care.
Deadline: 30 november 2022
The course Clinical Decision-Making for Drug-Resistant Tuberculosis (DR-TB) offers vast knowledge on the epidemiology, diagnostics and treatment of this still very relevant disease. It consists of an online phase with modules for self learning and group work, as well as a face-to-face phase in Antwerp. During this course, you get advice on how to interpret specific tests, including mechanisms and detailed interpretation of important diagnostic tools such as GeneXpert (Ultra) or line probe assays, as well as knowledge on how to proceed in resource-limited settings where drug susceptibility testing for second-line drugs is limited and how to determine the therapeutic threshold for the initiation of (DR-)TB treatment. Case discussions will help you to improve your problem-solving skills. You will have the opportunity to discuss with colleagues from different settings their diverse experiences with DR-TB. At the end of this course, you will feel confident to construct a robust individualised DR-TB regimen. For specific questions, there are experts available from different fields and parts of the world, who are all very enthusiastic to share their knowledge. This course is not only helpful for people that are new to this field, but also for clinicians with many years of experience, as they can gain important insights on how to improve their DR-TB management and care on a programmatic and individual level.
Tabitha Abbew Elisabeth
Much of my professional life has been in tuberculosis and managing drug-resistant tuberculosis patients in the central region of Ghana. ITM’s Drug-resistant Tuberculosis (DR-TB) course offers an immense knowledge base in all aspects of tuberculosis case management. I mainly found the elements of clinical decision-making on difficult-to-treat patients fascinating. There is essential teaching on the addition of clinical history, investigations and the context to decide to treat and, after that, a well-designed way of constructing an individualised regimen based on scientific evidence. Back home, I have implemented some of these learnings in building regimens for patients who are failing other regimens and supporting clinicians in this stead. So regardless of your years of experience in the field of drug-resistant tuberculosis or being a novice, this course is excellent for you if you want to find yourself in TB case management and research.